Cannara Biotech (STU:8CB0) 3-Year Revenue Growth Rate : 161.10% (As of May. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Cannara Biotech 3-Year Revenue Growth Rate?

Cannara Biotech's Revenue per Share for the three months ended in May. 2024 was €0.15.

During the past 12 months, Cannara Biotech's average Revenue per Share Growth Rate was 47.90% per year. During the past 3 years, the average Revenue per Share Growth Rate was 161.10% per year. During the past 5 years, the average Revenue per Share Growth Rate was 154.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 6 years, the highest 3-Year average Revenue per Share Growth Rate of Cannara Biotech was 233.20% per year. The lowest was 128.90% per year. And the median was 161.10% per year.

Competitive Comparison of Cannara Biotech's 3-Year Revenue Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Cannara Biotech's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cannara Biotech's 3-Year Revenue Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cannara Biotech's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Cannara Biotech's 3-Year Revenue Growth Rate falls into.

Cannara Biotech 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Cannara Biotech (STU:8CB0) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

Cannara Biotech 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Cannara Biotech's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Cannara Biotech Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cannara Biotech Inc (STU:8CB0) » Definitions » 3-Year Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

LOVFF:USA LOVE:Canada

Address

1055 West Georgia Street, Suite 2050, Vancouver, BC, CAN, V6E 3P3

Website

http://www.cannara.ca

Cannara Biotech Inc is a vertically integrated producer of premium-grade cannabis and cannabis-derivative products for Canadian markets. The company owns two mega Quebec-based facilities. The company operates in in two segments; Indoor cannabis operations segment which includes the cultivation, processing and sale of dried cannabis and cannabis derivatives for the Canadian market and the Real estate operations segment related to the Farnham and Valleyfield building. Majority of the revenue for the company is generated from its Cannabis operations segment. .

Cannara Biotech Headlines

No Headlines